Last updated: February 16, 2026
What is the current market status of the drug with NDC 60219-1585?
The drug identified by NDC 60219-1585 is Leqembi (lecanemab), developed by Eisai and Biogen. Approved by the FDA in January 2023 for treatment of Alzheimer’s disease, it is the first monoclonal antibody targeting amyloid beta to receive approval. As of early 2023, the drug has started commercialization, with infusion centers and healthcare providers gradually integrating it into clinical practice.
Market penetration remains limited initially due to manufacturer supply constraints, payer negotiations, and clinical adoption hurdles. The number of prescriptions is expected to grow as awareness and infrastructure expand.
Revenue forecasts suggest a slow start, with estimates ranging from $200 million to $500 million in the first year, based on prescriber adoption projections and patient eligibility.
How does the competitive landscape influence pricing?
Leqembi faces competition from existing Alzheimer’s treatments like Aduhelm (aducanumab) and Lecanemab (from Eisai). The pricing strategies for these drugs set a baseline.
| Drug |
Approved (date) |
Market strategy |
Launch Price (approximate) |
| Aduhelm (aducanumab) |
June 2021 |
High initial price, value-based agreements |
$56,000 per year |
| Leqembi (lecanemab) |
January 2023 |
Competitive, similar to Aduhelm |
$26,500 per year (estimated) |
Leqembi's lower list price aims to differentiate itself amid payers' reimbursement pressure. Negotiations with Medicare and private insurers influence net pricing significantly.
Pricing considerations set by the manufacturer include cost of therapy, administration (intravenous infusion), and monitoring. Reimbursement coverage is vital; Medicare announced coverage with utilization management protocols, which could limit access and thus influence revenue.
What are possible price projections over the next three years?
Annual price adjustments depend on multiple factors: insurance negotiations, manufacturing costs, market acceptance, and emerging competition. Currently, the initial list price is around $26,500 per patient annually.
| Year |
Expected average price (approximate) |
Key factors |
| 2023 |
$26,500 |
Initial list price, payer negotiations commence |
| 2024 |
$24,000–$28,000 |
Payer discounts, utilization management |
| 2025 |
$22,000–$26,000 |
Increased competition from other anti-amyloid drugs; cost containment measures |
Decrease in net price may result from negotiations and stricter utilization controls, particularly with Medicare. The presence of copays, deductibles, and prior authorization requirements will influence actual patient access and revenue.
How do reimbursement policies impact the pricing outlook?
Reimbursement policies are critical. Medicare's announcement in July 2023 for coverage with prior authorization restricts initial access, likely suppressing patient volume and revenue in the short term.
Private insurers follow Medicare’s lead, with many mimicking the coverage rules. Contractual agreements may include discounts, leading to net prices that are significantly below the list price.
Despite potential for high gross revenues, payer restrictions could constrain market penetration and reduce effective pricing, especially in the first two years.
What are the risks affecting future pricing projections?
Multiple factors could alter projections:
- Regulatory decisions: Approval of additional indications or change in usage guidelines.
- Market uptake: Slow adoption due to safety concerns, reimbursement hurdles, or clinician familiarity.
- Competitive entry: New therapeutics targeting similar pathways could exert downward pressure.
- Cost of manufacturing and supply chain: Any disruption could influence margins.
- Patient volume growth: Limited by diagnosis rates and access barriers.
Key Takeaways
- NDC 60219-1585 is lecanemab (Leqembi), FDA-approved in January 2023.
- Market adoption is increasing as infrastructure develops; revenue remains moderate initially.
- Launch price around $26,500 per year; future prices likely to decrease due to payer negotiations.
- Reimbursement policies through Medicare and private insurers heavily influence net revenue.
- Market risks include regulatory shifts, competition, and adoption rate fluctuations.
FAQs
1. What is the primary indication of Leqembi?
It is approved for early-stage Alzheimer’s disease to slow cognitive decline.
2. How does Leqembi compare in price to competing therapies?
Its initial list price is roughly half that of Aduhelm, which is approximately $56,000 annually.
3. What factors determine reimbursement levels for Leqembi?
Payer negotiations, clinical guidelines, utilization management policies, and patient eligibility criteria.
4. How does clinical adoption of Leqembi influence its market value?
Wider adoption increases revenue; slow uptake limits it, affecting overall market projections.
5. Are there upcoming patents or exclusivity periods for Leqembi?
Patents related to monoclonal antibody technology typically extend for 10-15 years from approval, providing market exclusivity during this period.
Citations
- FDA. (2023). "FDA Approves Leqembi for Alzheimer’s Disease."
- Eisai Co. Ltd. (2023). "Leqembi (lecanemab) Prescribing Information."
- Medicare Coverage Announcement. (2023). Centers for Medicare & Medicaid Services.
- MarketWatch. (2023). "Alzheimer’s drug pricing and market forecasts."
- EvaluatePharma. (2023). "Biopharma Pricing & Market Projections."
